Osteoarthritis (OA) is a degenerative joint disease characterised by a progressive degradation of articular cartilage and underlaying bone and is associated with pain and disability. Currently, there is no medical treatment to reverse or even retard OA. Based on our previous reports, where we establish the repair potential of short Link N (sLN) in the intervertebral disc, a cartilage-like tissue, we hypothesise that sLN may hold similar promises in the repair of articular cartilage. This study aimed to determine if sLN, could prevent OA disease progression.
Introduction
Articular cartilage is composed of a dense extracellular matrix (ECM) and a sparse distribution of chondrocytes (Poole et al., 2002; Bayliss and Ali, 1978) . Water, collagen and proteoglycans, with other noncollagenous proteins, are present in the ECM. Collagens and proteoglycans are the major macromolecules directly responsible for the viscoelastic load-bearing properties of the articular cartilage. Chondrocytes maintain cartilage ECM by the low-turnover replacement of matrix components. During aging and joint disease, this equilibrium is disrupted and the rate of loss of collagens and proteoglycans from the ECM exceeds the rate of deposition of newly synthesised molecules (Aurich et al., 2006) .
Several events trigger joint cartilage destruction, including changes in the mechanical environment, biochemical changes in the ECM, and biological responses of chondrocytes, subchondral bone and synovium to inflammation (Goldring and Otero, www.ecmjournal.org J Antoniou et al. sLink N acts as a DMOAD 2011; Roughley, 2001) . Osteoarthritis (OA) is a heterogeneous degenerative joint disease in which different causes can result in articular cartilage damage and the destruction of the whole joint. Primary, or idiopathic OA is characterised by a slow progressive degeneration of articular cartilage, increased density or erosion of the subchondral bone, formation of osteophytes, inflammation of the synovium, degeneration of ligaments and the menisci, and hypertrophy of the joint capsule (Conaghan et al., 2015) . It is the most common cause of mobility loss, severely affecting the quality of life, work productivity and cost of healthcare, and represents the most prevalent form of musculoskeletal disease worldwide (Elders, 2000; Poole et al., 2002) . Other diseases or conditions such as obesity, diabetes, hormone disorders abnormally formed joints at birth (congenital), uric acid crystals in gout, rheumatoid arthritis and other inflammatory conditions of the joints, cause secondary OA increasing mechanical stress on cartilage and repeated trauma to the joint structures (ligaments, bones and cartilage) (Henriksen et al., 2013) . Increased morbidity associated with OA has been shown to contribute indirectly to an increased mortality (Kluzek et al., 2016) . However, no drugs are available to modify OA disease progression and current clinical OA management is mainly concerned with symptom reduction, e.g. pain and joint swelling/ stiffness, with oral non-steroidal anti-inflammatory drugs (NSAIDs) as pharmacological treatment at mid-stage of the disease, and arthroplasty, an irreversible procedure, as the final solution to maintain joint function. Timely intervention at early stage in OA progression is critical for preventing or delaying disease development and a key target in preserving proper joint function.
Link N (DHLSDNYTLDHDRAIH), is the 16-amino acid N terminal region of human link protein, a glycoprotein that stabilises proteoglycan aggregates, which are the major constituents of the extracellular matrix of hyaline cartilage and intervertebral discs (IVDs). It has been shown to increase both collagen and proteoglycan synthesis in chondrocytes (McKenna et al. 1998) , in nucleus pulposus cells in vitro, and in ex vivo intact human IVDs (Gawri et al., 2013; Mwale et al., 2003) . Furthermore, it was able to increase disc height in a rabbit model of disc degeneration . Recent evidence indicates that Link N activates Smad1/5 signalling in cultured rabbit IVD cells by binding to the bone morphogenetic protein (BMP) type II receptor and upregulating the expression of growth factor BMP-7 (Wang et al., 2013) . In addition, Link N was shown to suppress markers of pain in human IVD cells (Noorwali et al., 2018) . Link N may therefore provide a therapeutic benefit not only to degenerating discs but also to articular cartilage because of the similar composition of the extracellular matrix. Although Link N can activate the BMP pathway, it does not stimulate bone formation as has been demonstrated with direct application of BMP growth factors (Antoniou et al., 2012; Wang et al., 2013) .
Recently, we found that the first 1-8 residues of Link N (short Link N, sLN) are responsible for its biological activity (Gawri et al., 2014) and that this short peptide can increase proteoglycan synthesis in both types of IVD cells, even in an inflammatory milieu. sLN can stimulate the synthesis of type II collagen and aggrecan in a long-term whole disc organ culture (AlGarni et al., 2016) . Recently, it was shown that sLN is as good as Link N in stimulating proteoglycan content and increasing disc height when administered to the degenerate rabbit disc in vivo at half the molar mass previously shown to be effective with Link N (Mwale et al., 2018) . Thus, although sLN appears to be effective at stimulating repair of the IVD in vivo, it remains unknown whether a similar mechanism exists in the repair of other tissues such as cartilage (Antoniou et al., 2012; Liu et al., 1999; Liu et al., 2000; McKenna et al., 1998; Wang et al., 2013) .
The purpose of the present study was to determine if sLN could prevent disease progression in a rabbit model of OA.
Materials and Methods

Experimental animals
All animal studies were performed in accordance with the requirements of the Canadian Council on Animal Care. Local ethics committee approval was obtained from the "Comité d'éthique de l'utilisation des animaux (CÉUA)" at the Faculty of Veterinary Medicine, Université de Montréal. Twenty two skeletally mature female (8 months old) New Zealand white rabbits (Charles River, St. Constant, Quebec, Canada) with a mean weight of 3.9 kg (range: 3.4-5.1 kg) were used for this study. Rabbits were housed separately and permitted free cage activity for the duration of the study.
Experimental Design
A schematic diagram of the study timeline is presented in Fig. 1 . Briefly, animals (n = 22 rabbits) were randomly divided into 3 groups: 8 rabbits for anterior cruciate ligament transection (ACLT) Fig. 1 . Schematic presentation of the study timeline.
Rabbit arrivals
100 μg sLink N (sLN) www.ecmjournal.org followed by sLN treatment, 8 rabbits for ACLT followed by saline treatment, and 6 sham-operated controls without ACLT or any further treatments. Digital radiographs (dorso-plantar and latero-medial views) of all femorotibial joints were performed two weeks prior to surgery, under full sedation, to exclude animals with joint pathology. All unilateral ACLT surgeries were performed at day 0 in 16 rabbits.
Short Link N (sLN) DHLSDNYT (Link N 1-8) with a mass of 964 Da was synthesised by CanPeptide (Pointe Claire, QC, Canada). Treatment was administrated at 3, 6 and 9 weeks post ACLT by intra-articular injections into the operated knee using either 100 µg sLN in 1 mL saline for the sLN group (n = 8 rabbits) or 1 mL saline (vehicle) for the saline group (n = 8). All animals were sacrificed 12 weeks post ACLT surgery. The rabbits were weighed before surgery, before each injection and at the end of the study. One of the rabbits assigned to the sLN group showed abnormal behaviour and weight gain before and after surgery (32 % over the average) and was excluded from the study.
ACLT surgeries
All surgeries were performed by a board-certified veterinary surgeon (specialist) as described previously (Bouchgua et al., 2009) . Trimethoprimsulfamide (Tribissen 24 %, Schering-Plough Animal Health, Pointe-Claire, QC, Canada), 15 mg/kg, SC, was administered pre-operatively. Rabbits were then pre-medicated, and anaesthesia was induced with xylazine (Novopharm Limited, Animal Health, Toronto, Canada) 5 mg/kg, intramuscular, and ketamine (Bioniche, Animal Health Canada Inc.) 20 mg/kg, intramuscular. Anaesthesia was maintained with 2-2.75 % isoflurane (Baxter Corporation, Mississauga, Canada) via an orotracheal tube, under the supervision of a board-certified veterinary anaesthesiologist. The anterior cruciate ligament (ACL) was transected through a medial parapatellar incision. After ACL transection (ACLT) the skin was subsequently sutured. Analgesia was achieved with the administration of buprenorphine (ScheringPlough Ltd, Welwyn Garden City, UK) 0.03 mg/ kg, subcutaneous, pre-operatively and 12 h later. A fentanyl patch, 25 µg/h, was applied to the lumbar region for 72 h (Duragesic 25, Fentanyl Transdermal System, Janssen-Ortho Inc., Markham, Ontario, Canada) (Bouchgua et al., 2009) .
Intraarticular Injections
Injections were prepared in an aseptic manner, under a biological hood, prior to intra-articular injection. Rabbits were anaesthetised with midazolam 0.2 mg/kg (Midazolam Sandoz, Sandoz Canada, Boucherville, QC) and dexmetetomidine 0.1 mg/ kg mix, intramuscular (Dex-domitor, Zoetis Canada, Kirkland, QC) and Alfaxalone 4 mg/mL, intramuscular, Zoetis Canada (Alfaxan, Jurox, Rutherford, NSW, Australia) 20 min before injection. The knee was clipped, if there was excess hair, and alcohol was applied over the femoropatellar joint and the limb placed in extension and the central patellar ligament identified. The limb was then placed in slight flexion and the injection was performed under the patella and into the suprapatellar pouch with a 25G × ¾″ needle. Ten flexions/extensions of the limb were then performed to distribute the treatment evenly within the joint space.
Macroscopic evaluation of joint integrity
Following euthanasia, the treated femorotibial joints were carefully opened and a map of articular cartilage lesions was performed manually for each joint, after the application of Indian ink to accentuate fibrillation and erosion as described previously (Laverty et al., 2010) . Indian ink adheres to fissured cartilage providing contrast with surrounding normal cartilage (Meachim, 1972) . The lesions in each compartment (medial femoral condyle [MFC] , lateral femoral condyle [LFC] , medial tibial plateau [MTP] , and lateral tibial plateau [LTP]) were measured and scored by evaluators blinded to the treatment groups according to the criteria outlined in Table 1 (Laverty et al., 2010) . Digital images of all the femorotibial articulating surfaces were acquired using a Rebel camera (Nikon, Tokyo, Japan).
Histologic assessment of lesion severity and immunohistochemistry
The femorotibial joints were harvested and fixed in 10 % neutral-buffered formalin. The specimens were then cut with an ISOMET saw (Buehler, Illinois, USA) with a 15 HC diamond blade (10.2 mm × 0.3 mm). Sagittal sections were obtained from each femoral condyle and tibial plateau, centred on the most severe lesion. This was performed by visualisation and consultation with corresponding manual maps and digital images. The tissue blocks were decalcified Scores for macroscopic joint integrity 1 = Surface normal in appearance and does not retain Indian ink (Intact surface) 2 = Fibrillation < 4 mm 3 = 4 mm ≤ Fibrillation < 8 mm 4 = Fibrillation ≥ 8 mm 5 = Erosion < 2 mm 6 = 2 mm ≤ Erosion < 5 mm 7 = Erosion ≥ 5 mm Table 1 . Macroscopic scale for joint integrity. J Antoniou et al. sLink N acts as a DMOAD for 2 weeks with 14 % ethylenediaminetetraacetic acid solution (Fisher Scientific, Nepean, Ontario), dehydrated through graded alcohols and cleared with toluol prior to being embedded in paraffin wax. 5 µm sections were then stained with safranin O-fast green for histological assessment. Multiple sections were also made from normal femoral condyles and tibial plateaus to serve as controls for the assessors. Three independent evaluators, all with prior experience assessing histopathology in this model and including a veterinary American board-certified pathologist, blindly assessed the histological changes employing a previously published scoring system ( Table 2 ) (Laverty et al., 2010) . Sections were deparaffinised and hydrated as previously described (AlGarni et al., 2016 
RNA extraction and quantitative real-time PCR
Three different lots of normal human-knee chondrocytes were purchased from Lonza, Basel, Switzerland. Cells were cultured as micro-pellets at a density of 2.5 × 10 5 cells/pellet prior to treatment. Pellets were treated for 48 h with 0.5 mL medium supplemented with 0.25 µg sLN or with vehicle (PBS) alone as a control. Total RNA was extracted using a total RNA mini-kit (Geneaid Biotech Ltd., Taiwan) following manufacturer's instructions. Complementary DNA was synthesised using a Histochemical/histological assessment of articular lesions severity Parameters: Safranin O -fast green staining 0 = uniform staining throughout articular cartilage 1 = loss of staining in superficial zone of hyaline cartilage< 50 % the length of the condyle or plateau 2 = loss of staining in superficial zone of hyaline cartilage ≥ 50 % the length of the condyle or plateau 3 = loss of staining in the upper ⅔ of hyaline cartilage < 50 % the length of the condyle or plateau 4 = loss of staining in the upper ⅔ hyaline cartilage ≥ 50 % the length of the condyle or plateau 5 = loss of staining in all the hyaline cartilage < 50 % the length of the condyle or plateau 6 = loss of staining in all the hyaline cartilage ≥ 50 % the length of the condyle or plateau Structure 0 = normal 1 = surface irregularities 2 = fissures in < 50 % surface 3 = fissures in ≥ 50 % surface 4 = erosion ⅓ hyaline cartilage< 50 % surface 5 = erosion ⅓ hyaline cartilage ≥ 50 % surface 6 = erosion ⅔ hyaline cartilage < 50 % surface 7 = erosion ⅔ hyaline cartilage ≥ 50 % surface 8 = Full depth erosion hyaline cartilage < 50 % surface 9 = Full depth erosion hyaline cartilage ≥ 50 % surface 10 = Full depth erosion hyaline and calcified cartilage to the subchondral bone< 50 % surface 11 = Full depth erosion hyaline and calcified cartilage to the subchondral bone ≥ 50 % surface Chondrocyte density 0 = no decrease in cells 1 = focal* decrease in cells 2 = multifocal † decrease in cells 3 = multifocal confluent † † decrease in cells 4 = Diffuse decrease in cells Cluster formation 0 = normal 1 = < 4 clusters 2 = ≥ 4 but < 8 clusters 3 = ≥ 8 clusters Table 2 . Histochemical/histological assessment of articular lesions severity in the ACLT rabbit model of osteoarthritis (Laverty et al., 2010) . *observed at one site on section. †observed at more than one site. † †observed at multiple sites that are in contact. www.ecmjournal.org superscript Vilo cDNA synthesis kit (Thermo Fisher Scientific, Waltham, MA). Quantitative real-time PCR of human BMP -2, -4 and -7 was quantified by ABI 7500 fast light cycler using CYBR green master mix (Thermo Fisher Scientific, Waltham, MA) and specific primers (BMP2: Forward-AGTTTATCACCTCAGCAGA; Reverse-CACTTCCACCACGAATCCAT; BMP4: Forward-TAACCTCAGCAGCATCCCT, Reverse-TGGTGGGTCCGAGTCTGAT; BMP7: Forward-A G AT G C A G C G C G A G AT C C T C , R e v e r s e -TGGTAGCGTGGGTGGAAGAAT). Relative mRNA expression level was normalised against GAPDH, as previously described (Antoniou et al., 2012) . The one-way analysis of variance (ANOVA) followed by Holm-Sidak's multiple comparisons test was used to assess differences in BMP expression. p-values equal to or less than 0.05 were deemed statistically significant.
Statistical analyses Macroscopic evaluation of joint integrity
For the categorical variables (scores of the macroscopic evaluation), the macroscopic grades were divided into 2 categories: non-diseased joints with intact surface and diseased joints with evident fibrillation or erosion. A Fisher's exact test was used to compare proportions between sLN and Saline groups.
Histologic assessment of lesion severity
Categorical variables (the histologic parameters scores at the lesion site) were summarised using frequency distribution per grade. Joint OA score was calculated as the sum of the histologic parameters for each compartment of the knee (safranin O-fast green staining, structure, chondrocyte loss, chondrocyte clusters, tidemark integrity scores). The one-way analysis of variance (ANOVA) followed by HolmSidak's multiple comparisons test was used to assess differences between the sLN, saline and saline groups with respect to OA lesion severity. p-values equal to or less than 0.05 were deemed statistically significant. An intra-class coefficient was employed to assess agreement between reviewers for histological assessment (safranin O-fast green and structural scores). Following this independent review, the reviewers met to create a consensus score on samples with a divergence of greater than 2 points.
Results
Macroscopic joint integrity
In all joint compartments of the sham group, the articular cartilage surface presented an intact macroscopic appearance with no sign of lesion. In the saline group, fibrillation and prominent erosion occurred in both femoral condyle compartments and the lateral compartment of the tibial plateau (Fig. 2) . The macroscopic grade data, categorised as diseased (overt fibrillation and cartilage erosion) or non-diseased, showed 75 % of the saline group with disease in the MFC compartment, compared with 14.3 % in the sLN group (p = 0.041). This indicated a statistically significant lower severity of disease for the sLN group compared with the saline group at this site (Table 3) . sLN treatment reduced the severity of the macroscopic cartilage damage in the three compartments of the knee showing erosion. In the LTP and MFC, sLN prevented the erosion, and Fig. 2 . Macroscopic assessment of the articular surfaces of the knee's compartments. All femorotibial joint compartments in all animals were examined for gross morphologic changes of the articular cartilage and were graded following application of Indian ink; medial femoral condyle (MFC), lateral femoral condyle (LFC), medial tibial plateau (MTP), and lateral tibial plateau (LTP). The 7 grades were divided into 2 categories: diseased joints with evident fibrillation or erosion (scores 3 to 7) and non-diseased joints (scores 1 and 2). A Fisher's exact test was used to compare the Saline with the sLN group (percentages of animals with disease in each compartment; Fisher's exact test; *p = 0.041). sLink N acts as a DMOAD reduceed erosion in the LFC compartment. In the MTP compartment, no erosions occured in either treatment group. There was a significant reduction in the number of erosions on the MFC and a trend in the LTP and LFC compartments. Thus, sLN prevented the severity of the macroscopic damage of the articular cartilage (Fig. 3) .
Histologic assessment of the lesion severity Structural parameters
Histological assessment of safranin-O staining, fissures and erosion of cartilage was performed in order to determine whether sLN has structure modifying properties in the OA joint (Laverty et al., 2010) . With respect to histological structural parameter changes, at the end of the study the cartilage in the sham group presented a normal aspect or some fibrillation but never erosions, while partial and full depth erosions were present in 24 (75 %) compartments of the saline group (Table 4) . sLN treatment eliminated full depth erosion observed in the saline group. Reduction of lesion severity was observed throughout all the joint compartments with sLN. In the individual compartments, the MFC, LFC and the LTP behaved similarly whereas the MTP showed less severe degradation (no partial erosion) ( 
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compartments were examined, similar results were observed with preservation of safranin O by sLN (Table 3) .
Cellularity and Cluster assessment
Cellularity of articular cartilage was assessed to determine whether chondrocyte loss or cluster formation was influenced by sLN (Table 4 ). In the presence of saline, there was evidence of decreased cell density which appeared to be minimised by the administration of sLink N. Cluster formation was not observed in the sham control, but was a feature of degenerated cartilage of the saline group. sLN had minimal effect on cluster formation (Table 4) .
Total joint scores
OA score decreased significantly (p = 0.0118) in the joints of sLN-treated rabbits compared with salinetreated rabbits (Fig. 4) . Joint OA score www.ecmjournal.org cartilage fibrillation or erosion to show the effect of increase in joint score.
sLN upregulates BMP 2 expression in chondrocytes BMP-2 and -7, have been associated in cartilage repair. In rabbit nucleus pulposus cells, upregulation of BMP-7 and -4 was described as a mechanism for Link N in IVD repair (Wang et al., 2013) . To determine whether a similar mechanism exists in our rabbit model of OA, the expression of BMP-2, -4 and -7 were verified in rabbit knee joints treated with sLN compared with sham and saline controls. Although sham animals demonstrated an expression profile for BMP-2, this pattern was lost in saline-treated joints. However, in the sLN treated group, BMP-2 expression was strongly present (Fig. 6 ). Unlike BMP-2, BMP-4 and -7 expression was absent in the joints of all treated animals (Fig. 6) . Previous studies have shown that Link N stimulates both proteoglycan and collagen synthesis (McKenna et al., 1998; Liu et al., 2000) in human articular cartilage. However, a mechanism has not been described. To determine whether sLN induces a similar effect in human chondrocytes on BMP expression as demonstrated in our rabbit model (Fig. 6) , chondrocytes cultured in micro-pellets were treated with sLN for 48 h. Gene expression data indicate that only BMP 2 is significantly upregulated in chondrocytes following sLN treatment (Fig. 7) .
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Discussion
Previous in vivo studies have established the repair potential of Link N and sLN in the intervertebral disc, in a rabbit model of disc degeneration Mwale et al., 2018) . Several other in vitro studies have demonstrated that Link N promotes the matrix production in explant cultures of normal human articular cartilage (McKenna et al., 1998; Liu et al., 1999; Liu et al., 2000) . In the present study evidence is provided that sLN could prevent OA lesion development or progression in vivo in an ACLT rabbit model of OA. Data indicated that sLN had a protective effect on the severity of cartilage degeneration during the development of OA that occurred in the LTP, LFC and MFC compartments of the knee, which in the absence of sLN showed prominent erosion. However, sLN had no apparent effect in the MTP compartment. This may be related to the low level of cartilage pathology occurring at this site in the model, as only minor fibrillation was observed in the absence of sLN. It is possible that sLN may only prevent progression of fibrillation to erosion or that exogenous sLN does not affect normal cartilage turnover, but only exerts its influence once matrix degradation exceeds turnover. Although chondrocyte cluster formation was present in both saline and sLN treated animals, only the sLN treated group demonstrated increased proteoglycan content in knee cartilage suggesting a possible chondroprotective effect. The dosage of sLN was chosen based partly on previous work of intradiscal administration in a rabbit model of disc degeneration . Although the chosen dosage of 100 µg sLN was shown to be efficacious, the preliminary work on a lower dose (25 µg) of intraarticular injection demonstrated no additional improvement (data not shown). To make sure sLN gained access to all the joint surfaces, this was dissolved in 1 mL saline and the knees were flexed and extended multiple times. It was speculated that repeated knee injections of sLN every 3 weeks would allow for the gradual loss of sLN from the joint space and the amount left would be sufficient to prevent OA progression. Further pharmacokinetic studies will be required to determine the ideal dosage and joint residence time to optimise intra-articular peptide therapy. The experimental duration was selected based on previous studies showing that fibrillation and erosion can occur as early as 4 weeks post ACLT surgery (Spriet et al., 2005) and that 12 weeks is sufficient for lesions to develop with full depth cartilage erosion (Bouchgua et al., 2009; Laverty et al., 2010; Tiraloche et al., 2005) .
BMP signalling plays an integral role in skeletal development and bone formation (Salazar et al., 2016) . Evidence suggests that BMPs are also important in articular cartilage homeostasis. For instance, gradual wearing of articular cartilage was observed with age in mice with a conditional knockout to BMP-receptor type 1A (BMPR-1A), resembling the process of OA in humans (Rountree et al., 2004) . In addition, BMPR-1A expression corelated with the progression of OA in cartilage lesions of human knee joints. Evidence in patients with circumscribed cartilage lesions implicate BMP-2 as an important factor in cartilage repair as a statistically significant correlation was observed with improvement of functional knee scores following regenerating surgery (Schmal et al., 2010) .
In another study, upregulation of BMP-2 and increased BMP-2 signalling was also found following mechanical stress in cartilage explants (Dell'Accio et al., 2006) . In addition to mechanical stress, proinflammatory cytokines, interleukin (IL)-1β and tumour necrosis factor (TNF)-α can stimulate the expression of BMP-2 in chondrocytes suggesting localised inflammation can induce an anabolic response (Fukui et al., 2003) .
In addition to BMP-2, BMP-7 (osteogenic protein-1) has demonstrated an important role in articular cartilage homeostasis and repair (Stove et al., 2006; Sekiya et al., 2009; Hayashi et al., 2008; Badlani et al., 2008) . Delivery of BMP-7, by an osmotic pump to the joint, has been studied both in a prophylactic (Badlani et al., 2008) or therapeutic protocol (Rountree et al., 2004) . In the first study, administration of recombinant human BMP-7 at the same time as the ACLT led to decreased OA severity at a gross and histological level (Rountree et al., 2004) . At a microscopic level, BMP-7 treatment considerably decreased the amount of articular cartilage loss measured histologically. BMP-7 treatment 4 weeks after the ACLT to allow for formation of arthritis before treatment, although less effective, showed its potential to reduce degradation of articular cartilage in OA. Others, found that weekly intra-articular injection of BMP-7 was able to inhibit progression of OA in rabbits with ACLT (Hayashi et al., 2008) .
In vitro studies have also demonstrated that BMP-7 can stimulate proteoglycan synthesis in human OA chondrocytes (Stove et al., 2006) .
Our data indicated that sLN upregulates BMP-2 in human chondrocytes and throughout the lesion in our rabbit model of OA. Surprisingly unlike previous reports, where Link N was shown to induce disc repair through upregulation of BMP-7 and to a lesser extent of BMP-4 by interaction with the BMP type II receptor (Wang et al., 2013) , the current study suggested that the anabolic activity of sLN in cartilage may be operating through stimulation of BMP-2 expression.
Although the rabbit ACLT model is widely used to test disease-modifying OA drugs (DMOAD), it has its limitations. Clinical OA typically manifest over the course of several years not rapidly over a few weeks, as is the case in our ACLT model. Joint instability generated by ACLT provides a challenge for testing structure/DMOADs, as the instability induced by ACLT that caused the OA is maintained post-surgery and during treatment. This may arguably provide a greater hurdle for DMOAD www.ecmjournal.org discovery. The fact that the MFC is the site with the greatest loading (Yoshioka et al., 1996) and the most severely affected compartment in our ACLT model makes the beneficial effect of sLN even more remarkable. Thus, pharmacologically, sLN therapy could be a novel therapeutic approach for treating OA by preventing disease progression. Since ACLT affects mostly cartilage it would be beneficial to study sLN in different OA models to investigate changes on other tissues such as cortical bone and synovium since OA is a disease of the whole joint.
Currently, there is no therapy specifically targeting cell death in human OA. However, preclinical studies in animal models suggest that inhibition of caspases might be a viable option to slow OA progression (Del Carlo et al., 2008) . Intraarticular administration of sLN may have a chondroprotective effect, enhancing the synthesis of new cartilage matrix, in addition to preventing further matrix degradation. A second major advantage of sLN over a growth factor such as BMP-2 and BMP-7 for therapeutic use is its straightforward chemical synthesis versus the complex expression and purification of a recombinant protein.
In conclusion, the results suggest that intraarticular injection of sLN is a promising nonsurgical treatment for early symptomatic stages of OA progression. One of the holy grails in rheumatology has been the search for a DMOAD. Although there have been advances in our understanding of OA and the development of new agents and treatment strategies, there are no DMOAD on the market (Hunter, 2011) . Based on the findings of the current work, sLN represents one example that can be useful as a therapeutic agent with the features of a DMOAD.
